Josh Felker

Josh Felker is a Research Analyst at CB1, covering all medical & adult-use markets. Josh began covering the Canadian legalization initiative in November ’16 when the Canadian Task Force report signaled a real-world chance of legalization occurring. He has written extensively for FelkerInvesting.com before joining CB1 Capital. Josh is CSC accredited and has maintained a strict adherence to the Buffett/Munger/Klarrman-style of security analysis.